Heterogeneity of lipidomic profiles among lung cancer subtypes of patients

Abstract

Lung cancer is a leading cause of cancer‐related deaths with an increasing incidence and poor prognoses. To further understand the regulatory mechanisms of lipidomic profiles in lung cancer subtypes, we measure the profiles of plasma lipidome between health and patients with lung cancer or among patients with squamous cell carcinomas, adenocarcinoma or small cell lung cancer and to correct lipidomic and genomic profiles of lipid‐associated enzymes and proteins by integrating the data of large‐scale genome screening. Our studies demonstrated that circulating levels of PS and lysoPS significantly increased, while lysoPE and PE decreased in patients with lung cancer. Our data indicate that lung cancer‐specific and subtype‐specific lipidomics in the circulation are important to understand mechanisms of systemic metabolisms and identify diagnostic biomarkers and therapeutic targets. The carbon atoms, dual bonds or isomerism in the lipid molecule may play important roles in lung cancer cell differentiations and development. This is the first try to integrate lipidomic data with lipid protein‐associated genomic expression among lung cancer subtypes as the part of clinical trans‐omics. We found that a large number of lipid protein‐associated genes significantly change among cancer subtypes, with correlations with altered species and spatial structures of lipid metabolites.

Trans‐omic profiling between clinical phenoms and lipidomes among patients with different subtypes of lung cancer

“…We performed a pilot prospective study to compare the variation of lipidomic profiles between health and lung cancer, and among lung cancer subtypes, as well as to correlate lipidomics with circulating leukocyte transcriptional profiles and clinical phenomes. 3 The present study further investigated the difference of lipidomics among lung cancer subtypes with a special focus on subtype-specific lipid elements. Of measured lipid elements, levels of PE elements (36:2, 18:0/18:2, and 18:1/18:1) were significantly higher in SCLC than in healthy control and other lung cancer subtypes, whereas lysoPC (20:1 and 22:0 sn-position-1) and PC (19:0/19:0 and 19:0/21:2) levels in ADC were more than 1500-fold higher than in SCLC.…”

“…About 200 µL plasma was collected into a glass tube, into which 10 µL internal standard was added and then 5 mL of methanol:chloroform:formic acid (10:10:1), as reported previously. 3,15 This mixture was incubated at -20 • C overnight after vigorous shaking. Two milliliters of Hajra's reagent (0.2 M H 3 PO 4 , 1 M KCl) were dropped, blended, and centrifuged at 3000 rpm for 5 min.…”

“…[10][11][12] Our previous study demonstrated the difference of lipidomic profiles among patients with different lung cancer subtypes and the potential association between lipidomic phenotypes and gene expression of lipid metabolism-associated proteins and enzymes as a concept evaluation. 3 The present study furthermore investigated the values of trans-nodules cross-clinical phenomic and lipidomic network layers in the recognition of lung cancer subtypes (ADC, SCC, and SCLC), in order to understand clinical phenome-associated lipid changes or lipidomic phenotype-associated clinical phenomes. We also evaluated the differences of lipidomic profiles between male and female, various ages, early and late stages, with or without metastasis, body mass index (BMI) <22 or >22, and digital evaluation scores less or more than 90.…”

Clinical lipidomics: a new way to diagnose human diseases

“…More clinical trans-omics are integrated, more values clinical lipidomics will have. We recently measured the profiles of plasma lipidome between health and patients with squamous cell carcinomas, adenocarcinoma, or small cell lung cancer, compared the difference of lipidomic profiles between healthy and patients with lung cancer and between patients with various subtypes of lung cancer, as well as correct lipidomic and genomic profiles of lipid-associated enzymes and proteins by integrating the data of large-scale genome screening [5]. Our preliminary data indicate the clear difference of lipidomic profiles between healthy and patients with lung cancer, e.g.…”

Lipidomics: a promising cancer biomarker

“…Therefore, lipidomics is proposed as a viable method to monitor the prognosis, diagnosis and treatment of cancer and acts as a new cancer biomarkers. Lv et al recently published an initial clinical study on the profiles of plasma lipidome between health and patients with lung cancer or among patients with squamous cell carcinomas, adenocarcinoma, or small cell lung cancer [10]. This is the first time to study the heterogeneity of lipidomic profiles among lung cancer subtypes of patients by integrating lipidomic data with lipid protein-associated genomic expression among lung cancer subtypes.…”